---
title: "Alterity Therapeutics Seeks Quotation for New ASX Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299120002.md"
description: "Alterity Therapeutics (AU:ATH) has applied for the quotation of 50,000 new ordinary fully paid shares on the ASX, with an issue date of September 16, 2026. This modest issuance likely supports routine capital management or option exercises, slightly increasing free float and liquidity. The move reflects ongoing use of public equity markets. Currently, analyst ratings maintain a 'Buy' recommendation with a A$0.95 price target, despite the stock's year-to-date decline of 10.0% and a strong sell technical signal."
datetime: "2026-09-16T02:43:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299120002.md)
  - [en](https://longbridge.com/en/news/299120002.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299120002.md)
generator: "portal-rs"
---

# Alterity Therapeutics Seeks Quotation for New ASX Shares

Alterity Therapeutics ( (AU:ATH) ) has issued an update.

Alterity Therapeutics has applied for quotation of 50,000 new ordinary fully paid shares on the ASX, with an issue date of Sept. 16, 2026. The modest size of the issuance suggests a routine capital management move, potentially related to the exercise of options or conversion of securities, with limited immediate impact on the company’s overall market positioning.

The application under the ASX Listing Rules reflects Alterity’s ongoing use of public equity markets to support its operations. While details of the underlying transaction are not disclosed, the additional quoted securities slightly increase the company’s free float and may provide incremental liquidity for existing and prospective shareholders.

The most recent analyst rating on (AU:ATH) stock is a Buy  
 with a A$0.95 price target.  
 To see the full list of analyst forecasts on Alterity Therapeutics stock,  
 see the AU:ATH Stock Forecast page. 

**More about Alterity Therapeutics**

Alterity Therapeutics Limited is a biotechnology company listed on the ASX under the ticker ATH. The company focuses on developing therapeutic solutions, with its ordinary fully paid shares traded in the public markets as part of its capital-raising and investor engagement activities.

**YTD Price Performance:** -10.0%

**Average Trading Volume:** 280,520

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** A$105.4M

See more data about ATH stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ATH.AU](https://longbridge.com/en/quote/ATH.AU.md)

## Related News & Research

- [Insider Move at Biotech Firm Sparks Fresh Investor Interest](https://longbridge.com/en/news/298398581.md)
- [Alterity Therapeutics issues shares from exercise of listed options at A$0.5 each](https://longbridge.com/en/news/297504784.md)
- [Megalestari Epack Sentosaraya announces extraordinary shareholder meeting](https://longbridge.com/en/news/301553857.md)
- [Telia Lietuva, AB (TEL1L) Plans Up to 85 Layoffs in Dec 2026](https://longbridge.com/en/news/301542398.md)
- [BTS Acquires Edward Lynx, strengthening its position in the Nordics and in Europe](https://longbridge.com/en/news/301542403.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**